IPM Clocks ₹120788 Cr In Feb 2018

Indian companies maintained their dominance in the IPM with a share of 79 per cent and grew combined at a strong 11 per cent growth rate

THE INDIAN Pharmaceutical Market (IPM) clocked ₹ 120788 crores and grew at 6.3 per cent as of MAT February 2018 and was valued at ₹ 9992 crores for the month of February. The retail sector was valued at ₹ 102188 crores and showed a growth of 7.0 per cent. The growth for IPM was 10 per cent.

Top 10 companies showed a double digit growth of 11 per cent over SPLY and clocked a combined revenue of ₹ 4319 crores with their share slight decreasing and coming down to 43 per cent in the IPM. Rank 4-7 set of top 10 companies grew in double digits with Mankind (21 per cent), Alkem (16 per cent), Macleods (14 per cent) and Lupin (11 per cent) being amongst companies with strong growths. Companies in 11-20 bracket grew even better at 13 per cent combined where Aristo (19 per cent) and Glenmark (13 per cent) were among the fastest growing companies.

Top 10 brands in the IPM were valued at ₹ 322 crores combined and showed a growth of 9 per cent which was slightly lesser than the IPM. 7 of the top 10 brands showed double digit growth with Clavam (26 per cent) and Thyronorm (23 per cent) leading the way for the month of February 2018. Only Novomix (-21 per cent) showed de-growth among top 10 brands. Brands ranked 11- 20 grew strongly at 18 per cent combined growth where Panderm+ (56 per cent) and Monocef (36 per cent) were amongst the fastest growing. These brands were valued at ₹ 231 crore for the month.